Prity Yadav | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Ms. Prity Yadav | Cell Death Pathway | Best Researcher Award

Ms. Prity Yadav, UNIVERSITY OF RAJASTHAN, JAIPUR, India

Prity Yadav is a dedicated research scholar at the Department of Zoology, University of Rajasthan, Jaipur, India. Under the guidance of Prof. P.C. Mali, she is pursuing a PhD focused on nanotechnology and reproductive biomedicine. With a strong academic foundation including an M.Sc. in Zoology and CSIR-NET-JRF qualification, she currently receives the Senior Research Fellowship (SRF) from CSIR, Delhi. Her interdisciplinary research combines herbal medicine and nanoscience to develop eco-friendly contraceptive strategies, aiming to revolutionize non-hormonal fertility control. Prity has published 11 research papers in reputed journals indexed in SCI and Scopus, and actively contributes to the scientific community through her work. A member of the Indian Science Congress Association, she is passionate about public health, sustainability, and the responsible use of nanobiotechnology for population control and reproductive health. Her work holds significant promise for advancing global reproductive healthcare through innovative, natural, and non-invasive solutions.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Focused and Impactful Research Area
    Prity Yadav’s interdisciplinary research on nanotechnology and reproductive biomedicine is both relevant and innovative, especially in addressing global concerns like non-hormonal contraception, male fertility regulation, and eco-friendly biomedical alternatives.

  2. Consistent Publication Record
    With 11 publications in reputed SCI and Scopus-indexed journals, her research contributions are well-documented and consistently recognized in the academic community.

  3. Research Innovation
    Her work in green synthesis of silver nanoparticles using medicinal plant extracts for antifertility treatments reflects high originality and societal relevance.

  4. Academic Excellence
    She has cleared CSIR-NET-JRF and is currently receiving SRF from CSIR, showing national-level academic competitiveness.

  5. Sustainability and Public Health Focus
    Her projects promote natural, sustainable alternatives to conventional fertility control methods, aligning with public health policy and eco-conscious innovation.

  6. Active Membership in Scientific Community
    Her involvement in organizations such as The Indian Science Congress Association supports her engagement in broader scientific discourse.

🔧 Areas for Improvement:

  1. International Collaborations & Exposure
    Participation in international research collaborations, conferences, or exchange programs would further enrich her global perspective and strengthen her research profile.

  2. Patent Filing and Intellectual Property
    Considering the novelty of her nanoformulations, pursuing patents could enhance the impact and translational value of her work.

  3. Industry Engagement
    Involvement in consultancy or industry-based projects would bridge the gap between lab research and real-world application.

  4. Editorial and Peer Review Roles
    Taking on editorial responsibilities or peer-review contributions would boost her academic service profile.

🎓 Education:

Prity Yadav has a solid academic background in life sciences, specializing in Zoology. She completed her Master of Science (M.Sc.) in Zoology with distinction, focusing on reproductive physiology and applied biology. Demonstrating her academic excellence, she cleared the highly competitive CSIR-NET-JRF examination, qualifying for Junior Research Fellowship and later advancing to Senior Research Fellowship (SRF) funded by CSIR, New Delhi. She is currently enrolled in the PhD program at the University of Rajasthan, Jaipur, under the supervision of Prof. P.C. Mali in the Department of Zoology. Her academic path reflects a consistent focus on animal biology, toxicology, and molecular studies related to fertility and reproduction. Her strong theoretical knowledge, combined with hands-on laboratory training in nanoscience and biomedical research, sets a solid foundation for her innovative research. Prity’s education is a blend of traditional life sciences and modern interdisciplinary tools like nanotechnology and phytomedicine.

🧪 Experience:

Prity Yadav has accumulated significant research experience during her doctoral studies at the University of Rajasthan. With over four years of hands-on laboratory work, she has become proficient in nanoparticle synthesis, in vivo animal experimentation, biochemical analysis, and histopathological techniques. Her research focuses on developing green-synthesized silver nanoparticles using herbal extracts and evaluating their antifertility effects in male rodents. She has co-authored 11 publications in reputable journals and collaborated with fellow researchers on interdisciplinary projects involving herbal pharmacology, nanomedicine, and reproductive biology. While she has no direct industry consultancy experience, her academic research aligns closely with pharmaceutical applications. She frequently presents her findings in national and international conferences and is an active member of the Indian Science Congress Association. Prity’s experience highlights her commitment to scientific rigor, ethical research practices, and a vision for creating sustainable healthcare solutions through biocompatible nanotechnologies.

🔬 Research Focus:

Prity Yadav’s research lies at the intersection of nanotechnology and reproductive biomedicine, with an emphasis on developing herbal-based, non-hormonal antifertility agents. Her work explores the green synthesis of silver nanoparticles using medicinal plant extracts, aiming to enhance bioavailability and targeted delivery of active phytoconstituents. The ultimate goal of her research is to create eco-friendly, reversible male contraceptive methods with minimal side effects. She focuses on evaluating the impact of these nanoparticles on male reproductive systems through in vivo studies using rodent models. Her findings contribute to a deeper understanding of reproductive toxicity, oxidative stress, and fertility regulation mechanisms. This research addresses global challenges such as overpopulation and limited access to safe male contraceptives. Prity’s interdisciplinary approach supports sustainable healthcare by integrating traditional herbal knowledge with modern nanoscience, opening new avenues in contraceptive technology and public health policy.

📚 Publications Top Notes: 

  1. 🌿🔬 Herbal Nanoparticles to Control Fertility and Regulation: A Review

  2. 🧫🔥 Testicular Inflammation in Male Reproductive System

  3. 🍃🧪 Assessment of the Antifertility Potential of Silver Nanoparticles Synthesized Using Pongamia pinnata Leaf Extract in Male Wistar Rats

  4. 🌱📖 Medicinal Plants Potentials of Fertility Control, Antioxidant and Antimicrobial Activities: A Review

  5. 🧬🌿 Potential Antifertility and Antimicrobial Activities of Plants Used in Traditional Medicines: A Review

  6. 💊🦠 Cassia auriculata-Based Silver Nanoparticles: A Novel Approach to Combat Bacterial Infections

  7. 🌾🧠 A Review on Potential Antioxidant, Neuroprotective and Antidepressant Activities of Herbal Medicinal Plants

  8. ⚗️🧍‍♂️ Effects of Silver Nanoparticles of Putranjiva roxburghii on Reproductive Organs in Male Albino Rats

  9. 🌳🧬 Exploring the Impacts of Tecomella undulata Mediated Silver Nanoparticles on Male Rats Fertility and Reproductive Health

  10. 🍀🧫 An In Vitro Antioxidant Potential Analysis of Herbal Silver Nanoparticles Synthesized from Methanolic Leaf Extract of Cassia siamea

🧾 Conclusion:

Based on her scientific contributions, innovative research, and academic merit, Prity Yadav is a highly suitable candidate for the Best Researcher Award. Her work presents a unique and impactful solution to pressing challenges in public health and reproductive medicine. With scope for further growth in collaborative and translational domains, she stands out as a rising researcher making meaningful advances in her field.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.

 

Tao Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Tao Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Tao Zhang, South China Normal University, China

Dr. Tao Zhang is a distinguished Professor at the College of Biophotonics, South China Normal University, where he has been advancing the frontiers of chemical biology and phototheranostics. With a keen focus on developing innovative optical probes and imaging techniques for tumor diagnosis and treatment, Dr. Zhang has made significant contributions to the field of lanthanide chemistry and biomedical imaging. His academic journey spans from Ningbo University (MPhil) to earning his Ph.D. in Chemistry from Hong Kong Baptist University. As a corresponding author on numerous high-impact publications and a recipient of multiple prestigious provincial awards, Dr. Zhang has earned recognition for both research excellence and academic leadership. He is actively involved in interdisciplinary collaborations, producing over 40 peer-reviewed publications in journals such as Nature Communications, PNAS, JACS, and Advanced Science. His ongoing work addresses critical challenges in imaging-guided therapies for cancer under hypoxic and complex microenvironment conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📈 Outstanding Research Output
    Dr. Zhang has published over 40 peer-reviewed articles in top-tier journals such as Nature Communications, Advanced Science, JACS, ACS Nano, and PNAS. These works cover cutting-edge topics in photodynamic therapy, tumor imaging, and nanotechnology—key areas in modern biomedical research.

  2. 🧪 Innovation in Biomedical Chemistry
    He has demonstrated consistent originality by designing oxygen-independent Type I pro-photosensitizers, reversible ratiometric photoacoustic probes, and multimodal imaging nanoplatforms, all of which target real-world challenges in hypoxic tumor environments.

  3. 🌏 National Recognition
    His research excellence has been recognized by prestigious awards such as the Special Support Program for Young Top-notch Talents of Guangdong Province and the Pearl River Science and Technology Rising Star of Guangzhou, both in 2018.

  4. 🎯 Multidisciplinary Expertise
    With a strong background in lanthanide chemistry, chemical biology, and optical imaging, Dr. Zhang successfully bridges multiple fields, demonstrating a holistic approach to solving biomedical challenges.

  5. 📚 Leadership Role
    As a corresponding author on many publications, he plays a leading role in both research direction and execution. His progression from Assistant to Full Professor between 2014 and 2021 further reflects his capability as a research leader.

🛠️ Areas for Improvement:

  1. 🌐 International Collaborations & Visibility
    While Dr. Zhang has co-authored with international researchers, expanding his global collaborative network through joint grants, keynote talks, or leadership in international consortia could further enhance his profile.

  2. 👨‍🏫 Public Outreach & Technology Transfer
    Increasing efforts in public science communication, patenting innovations, or transitioning lab technologies into clinical trials could strengthen his case for broader societal impact.

  3. 📢 Social & Digital Engagement
    A higher digital or social media presence (e.g., ResearchGate, Google Scholar metrics, professional website updates) would make his research more visible to the global community and potential collaborators.

🎓 Education:

Dr. Tao Zhang embarked on his academic career with an MPhil in Inorganic Chemistry from Ningbo University (2006–2009), where he conducted research under Professor Hongze Liang. He furthered his education by pursuing a Ph.D. in Chemistry at Hong Kong Baptist University (2009–2013), mentored by Professors Wai-Kwok Wong and Ka-Leung Wong. His doctoral research focused on lanthanide coordination chemistry and bioimaging, setting a strong foundation for his future innovations in photodynamic therapy and tumor diagnostics. These formative years not only shaped his technical expertise in spectroscopy and nanomaterials but also cultivated a rigorous research ethic that has carried through his academic trajectory. His education was marked by cross-disciplinary training in synthetic chemistry, photophysics, and biological applications, providing him with a broad and robust skill set that continues to support his ongoing exploration in chemical biology and optical probes for clinical imaging and therapeutic interventions.

💼 Experience:

Dr. Zhang’s academic career at South China Normal University’s College of Biophotonics began in 2014 as an Assistant Professor. He was promoted to Associate Professor in 2017 and then to full Professor in 2021. Throughout his academic appointments, Dr. Zhang has led innovative research in tumor imaging, photothermal therapy, and optical diagnostics, establishing a productive research group known for creative nanoprobe design and translational research. His lab has secured multiple research grants and frequently collaborates with international researchers, combining chemical innovation with biomedical applications. Dr. Zhang has mentored graduate students and postdocs, many of whom have gone on to prestigious research positions. His steady academic progression reflects both his research productivity and leadership in the field of phototheranostics. Over the years, his expertise has positioned him at the forefront of integrating nanotechnology and chemistry into next-generation diagnostic and therapeutic platforms for treating cancer and understanding tumor microenvironments.

🏆 Awards and Honors:

Dr. Tao Zhang has received multiple prestigious awards that underscore his exceptional research contributions and scientific leadership. In 2018, he was honored with the Special Support Program for Young Top-notch Talents of Guangdong Province, recognizing his pioneering work in optical molecular probes for cancer imaging. That same year, he also received the Pearl River Science and Technology Rising Star of Guangzhou, further validating the impact and innovation of his interdisciplinary research in chemical biology. These accolades highlight his rising prominence as a researcher capable of translating basic chemical discoveries into practical medical technologies. He is consistently invited to contribute as a corresponding author in top-tier journals, reflecting the high regard his peers have for his scientific insight and rigor. These honors not only reflect personal achievement but also enhance the prestige of the College of Biophotonics at South China Normal University, where he continues to lead cutting-edge research.

🔍 Research Focus:

Dr. Tao Zhang’s research focuses on the convergence of Chemical Biology, Lanthanide Chemistry, and Optical Imaging Technologies for cancer diagnosis and treatment. His main interest lies in developing smart, light-activated nanomaterials and photosensitizers that enable precise imaging and phototherapy, particularly in hypoxic tumor microenvironments. His team is advancing Type I photodynamic therapy agents and oxygen-independent systems, addressing critical limitations in current cancer treatment modalities. Another core area of his research is the creation of upconversion nanoparticles and ratiometric probes for real-time, non-invasive imaging—capable of dual-modality functionality (fluorescence and photoacoustic). Leveraging lanthanide chemistry, Dr. Zhang also contributes to MRI contrast agent innovation and multimodal diagnostics. His cross-disciplinary work integrates synthetic chemistry, molecular design, and biological application, offering new avenues for theranostics. His cutting-edge research is published in leading journals, pushing the boundaries of tumor imaging, molecular sensing, and personalized cancer therapy with minimal invasiveness and enhanced specificity.

📚 Publications Top Notes:

  1. 🧬 Totally Caged Type I Pro-Photosensitizer for Oxygen-Independent Synergistic Phototherapy of Hypoxic Tumors – Advanced Science, 2024

  2. 🔁 Switching the NIR Upconversion of Nanoparticles for Orthogonal Activation of Photoacoustic Imaging and Phototherapy – Nature Communications, 2022

  3. 🧪 Dynamic-Reversible Photoacoustic Probe for Continuous Ratiometric Sensing and Imaging of Redox Status In Vivo – JACS, 2019

  4. 🎯 In Vivo Imaging-Guided Photothermal/Photoacoustic Synergistic Therapy with Tumor-Targeting Nanoparticles – ACS Nano, 2017

  5. 💥 In Vivo Selective Cancer-Tracking Gadolinium Eradicator as New-Generation Photodynamic Therapy Agent – PNAS, 2014

  6. 🧫 ROS-Catalytic Self-Amplifying Benzothiophenazine-Based Photosensitive Conjugates for Photodynamic-Immuno Therapy – Biomaterials, 2025

  7. 🧬 A Self-Catalytic UCNP-Based Nanomachine for Highly Sensitive Detection of CTCs – Biosensors and Bioelectronics, 2025

  8. 🔍 An AND-Gate Photoacoustic Probe for Cys and H2S Precise Photoacoustic Sensing in Tumors – Anal. Chem., 2024

  9. 🎨 Single Side-Chain-Modulatory of Hemicyanine for Fluorescence and Photoacoustic Dual-Modality Imaging – Small Methods, 2024

  10. 🌫️ High-Contrast Photoacoustic Imaging of Localized Cysteine in Breast Cancer – Chem. Eur. J., 2024

🧾 Conclusion:

Dr. Tao Zhang is highly suitable for the Best Researcher Award due to his exceptional scholarly output, innovative biomedical applications, and proven academic leadership. His work addresses some of the most critical challenges in cancer diagnostics and therapy using chemical tools and photonic technology.

Philippe Menasché | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Philippe Menasché | Stem Cell Research | Best Researcher Award

Prof. Philippe Menasché, AP-HP, France

Prof. Philippe Menasché, born on August 10, 1950, is a pioneering French cardiovascular surgeon and regenerative medicine researcher. Renowned globally for his work in cell therapy and heart failure, he performed the world’s first fetal stem cell transplantation in a human heart. With over four decades in medicine, he has blended surgical excellence with translational research, bridging the gap between bench and bedside. A professor since 1988, his leadership spans multiple roles—from senior hospital surgeon to director of major research teams at INSERM and the Carpentier Foundation. He has served as scientific advisor to health authorities and remains an active contributor to high-impact publications and international collaborations. A recipient of prestigious honors such as the Prix Galien and the Earl Bakken Award, Prof. Menasché continues to shape the future of cardiovascular regenerative therapy.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Clinical Innovation

    • Performed the first-in-man fetal stem cell transplantation for cardiac repair.

    • Led translational research turning basic stem cell science into clinical applications.

  2. Extensive Academic and Research Leadership

    • Over four decades of experience as a cardiovascular surgeon and academic leader.

    • Directed major units at INSERM, Carpentier Foundation, and Paris Hospitals.

  3. Global Recognition and Awards

    • Recipient of highly prestigious scientific prizes such as the Prix Galien (2016) and Earl Bakken Award (2011).

    • Recognized by top French and international medical societies.

  4. Recent and Relevant Research Impact

    • Active contributor to multicenter trials including ISCHEMIA, STROMA-CoV-2, and TRAUMACELL.

    • Publications in high-impact journals on cardiac regeneration, cell therapy, and stem cell-derived secretomes.

  5. Leadership in Science Policy and Ethics

    • President of the Medical and Scientific Council at France’s Agency of Biomedicine.

    • Advisor to the French Minister of Health (2005–2007), influencing national bioethics and translational policy.

⚠️ Areas for Improvement:

  1. Broader International Integration

    • While internationally recognized, deeper ongoing collaboration with North American and Asian biomedical consortia could further elevate global influence.

    • The upcoming visiting professorship at Columbia University (2025) is a strong step in this direction.

  2. Integration of AI & Digital Health

    • Limited evidence of work in AI-guided regenerative medicine, machine learning in cardiac diagnostics, or digital health integration in therapeutic development.

    • These areas represent major future growth potential in cardiac care.

  3. Mentorship Visibility

    • While his scientific contributions are vast, greater emphasis on training and mentoring the next generation of clinician-scientists would bolster his legacy.

📚 Education:

Prof. Menasché’s academic foundation is rooted in two pillars of French higher education. He earned his Doctor of Medicine (MD) from the Faculté de Médecine de Paris in 1979, graduating with honors, including the coveted Internship Golden Medal. He then pursued deeper inquiry into biomedical science, culminating in a Doctorate in Science (PhD) from Université Paris-Orsay in 1987. His dual training in clinical medicine and scientific research provided the ideal springboard for a career that integrates patient care with innovation. In 1988, he became a Professor of Thoracic and Cardiovascular Surgery, reflecting his command of both technical skill and academic leadership. His scholarly progression has also led to visiting roles abroad, including a forthcoming appointment as Visiting Professor in Biomedical Engineering at Columbia University in 2025. This cross-disciplinary education empowers his unique contribution to both surgical practice and regenerative cardiovascular therapies.

🏥 Experience:

Prof. Menasché began his medical journey in 1973 as an intern in Paris hospitals, ascending to Senior Staff Surgeon in 1988—a position he still holds. From 1995 to 2007, he served as Director of Research at the Surgical School of the Greater Paris Academic Hospitals. His research leadership extended to INSERM, where he directed Unit U633 and co-led regenerative therapy teams. He headed the Laboratory of Biosurgical Research at the Carpentier Foundation from 2002 to 2018. In parallel, he has played influential roles on regulatory and advisory boards, including as President of the Medical and Scientific Council of France’s Agency of Biomedicine. A dedicated member of multiple medical and scientific societies, Prof. Menasché has edited prestigious journals and contributed to over a dozen major clinical trials and collaborative studies. His experience combines clinical excellence, institutional leadership, and innovative research in heart failure and cell therapy.

🧬 Research Focus:

Prof. Menasché’s research is centered on regenerative medicine for cardiovascular diseases, particularly using stem cells and secretomes to repair damaged heart tissue post-myocardial infarction. His team explores therapeutic strategies involving pluripotent stem cell-derived cardiomyocytes, mesenchymal stromal cells, and extracellular vesicles to promote myocardial regeneration and immune modulation. He has led pioneering first-in-human trials, including the use of cell-derived secretomes in heart failure patients. His investigations bridge fundamental science with translational application, often conducted in multicenter randomized controlled trials. His work also intersects with neurological conditions, such as traumatic brain injury, using cell-based therapies to address neuroinflammation. Prof. Menasché is also involved in evaluating the safety and efficacy of stem cell-based interventions in ARDS, including COVID-19-associated cases. A central member of the European Society of Cardiology’s regenerative medicine group, he is advancing personalized and precise treatments for heart failure through novel biologics and bioengineering tools.

📄 Publications Top Notes:

  1. 🫀 Revitalizing the heart: strategies and tools for cardiomyocyte regeneration post-myocardial infarction

  2. 💉 Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

  3. 🫀📊 Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial

  4. 🧠🧪 Effects of intravascular administration of mesenchymal stromal cells…after traumatic brain injury (TRAUMACELL)

  5. 💓🧫 Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial

  6. 🦠🫁 Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells (STROMA-CoV-2)

  7. 🧬💗 Head-to-head comparison of relevant cell sources of small extracellular vesicles for cardiac repair

  8. 🫀💉 First-in-man use of a cardiovascular cell-derived secretome in heart failure – Case report

  9. 🧬🫀 Human PSC-derived cardiac cells and their products: therapies for cardiac repair

  10. 🫀🫄 Impact of Complete Revascularization in the ISCHEMIA Trial

📝 Conclusion:

Prof. Philippe Menasché is exceptionally qualified for the Best Researcher Award. His groundbreaking work in cardiac regeneration, commitment to translational medicine, and lasting contributions to surgical science and healthcare policy make him a uniquely impactful figure. His track record is not only defined by scientific innovation but also by societal relevance, particularly in addressing heart failure—a leading global health burden.

Tao Liang | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Mr. Tao Liang | Cell Death Pathway | Best Researcher Award

Mr. Tao Liang, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China

Dr. Tao Liang is an accomplished medicinal chemist with deep expertise in small molecule drug design, synthesis, and pharmacological evaluation. Originating from Dancheng County, Henan Province, and currently residing in Wuhu City, Anhui Province, Dr. Liang is an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. He earned his Doctor of Medicine from Shandong University, a leading institution under China’s “Double First-Class” initiative. With over 7 first-author SCI publications and multiple national invention patents, his research significantly contributes to targeted cancer therapies, especially involving HDAC6-selective inhibitors and Bax agonists. He has successfully led key projects funded by the Anhui Provincial Government and participated in prestigious National Natural Science Foundation of China projects. Known for both scientific depth and innovation, Dr. Liang has been recognized with national-level scholarships and university-wide honors for outstanding research achievements and academic excellence.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications

    • Authored 7 first-author SCI papers, including publications in top-tier journals like Acta Pharm Sin B (IF 14.907) and J Med Chem (IF 8.039).

    • Published extensively on HDAC6 isoform-selective inhibitors and apoptosis-targeting small molecules, a niche and cutting-edge domain in anticancer drug research.

  2. Research Leadership & Innovation

    • Serves as Principal Investigator for two key provincial research projects focusing on selective cancer therapies.

    • Demonstrated innovation in designing dual-target inhibitors (MMP/HDAC) and novel Bax agonists.

  3. National-Level Collaborations

    • Participated in major National Natural Science Foundation of China projects (5 total), totaling over RMB 2 million in funding.

    • Engaged with multidisciplinary teams and key opinion leaders, including renowned researchers such as Prof. Hao Fang and Prof. Xuben Hou.

  4. Academic Recognition

    • Winner of prestigious honors such as the National Scholarship, Outstanding Doctoral Graduate, and guest speaker at elite academic forums.

    • Recipient of 15+ national and university-level awards, including innovation prizes and scholarships.

  5. Patent Contributions

    • Holds 4 national invention patents, reflecting translational potential and real-world application of his research outputs.

🔧 Areas for Improvement:

  1. International Visibility & Collaboration

    • Current research impact is primarily within domestic circles (China). Engaging in cc, postdoctoral exchanges, or publishing with international co-authors would elevate recognition.

  2. Clinical Translation Pipeline

    • Despite strong preclinical development, there is no direct evidence of transition to clinical trials or industrial commercialization. Partnering with biotech/pharma could increase translational outcomes.

  3. Leadership Beyond Research

    • As an early-career researcher, administrative leadership (e.g., lab director, national committee memberships) may still be developing. Building a research group or mentoring PhD students would strengthen this.

  4. Interdisciplinary Expansion

    • Expertise is strong in medicinal chemistry, but cross-disciplinary projects involving AI/drug discovery, systems biology, or clinical oncology could broaden the impact.

🎓 Education:

Dr. Tao Liang received his Bachelor of Science in Pharmacy from Shandong University (2013.9–2017.6), one of China’s elite institutions under the National “985 Project” and “Double First-Class” initiative. Continuing at the same university, he pursued a Master’s and Ph.D. in Medicinal Chemistry, earning a Doctor of Medicine degree in 2022. Shandong University, renowned for its Ministry of Education Class A-rated disciplines, provided Dr. Liang with a rigorous scientific environment and access to state-of-the-art research facilities. During his academic training, he developed a strong foundation in chemical biology, natural product synthesis, and drug development. His educational journey has been marked by consistent excellence, earning him accolades like National Scholarships and Outstanding Graduate awards. His academic credentials and extensive research during his Ph.D. have positioned him as a leading young researcher in the field of medicinal chemistry in China.

💼 Work Experience:

Since August 2022, Dr. Tao Liang has been serving as an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. His research focuses on the structural design, chemical synthesis, and pharmacological activity evaluation of small molecule drugs, particularly targeting HDAC isoforms and apoptotic regulators like Bax. He currently leads two key projects: one on HDAC6-selective inhibitors and another on Bax agonists for cervical cancer therapy, funded by the Anhui Provincial Higher Education and Health Commission respectively. Previously, he participated in several high-impact national research projects, including two funded by the National Natural Science Foundation of China, focusing on anti-cancer drug discovery. His roles have involved both independent project leadership and critical collaboration within multidisciplinary teams. Dr. Liang’s work experience showcases his capabilities in translational medicinal chemistry research and positions him as a promising talent in pharmaceutical innovation.

🏆 Awards and Honors:

Dr. Tao Liang has received more than a dozen honors for his outstanding academic and research contributions. These include the prestigious National Scholarship (2021), Outstanding Doctoral Graduate of Shandong University (2022), and multiple first-class scholarships throughout his postgraduate studies. He was a special guest speaker at prominent forums like the “Haiyou Doctoral Forum” and “Lao Xu Talks about High Strategies.” His undergraduate years were equally distinguished, earning the first prize in the ‘Challenge Cup’ and honors like “Outstanding Graduate” and “Excellent Communist Youth League Member”. His early career was also decorated with international recognitions such as the First Prize for Innovation Results at the World University Students’ Pharmaceutical Garden Forum. These awards highlight both his academic brilliance and commitment to scientific advancement, affirming his eligibility and strength as a nominee for the Best Researcher Award.

🔬 Research Focus:

Dr. Tao Liang’s research centers on the design, synthesis, and biological evaluation of small molecule inhibitors with a primary focus on histone deacetylase 6 (HDAC6) isoform-selective inhibitors and Bax agonists for cancer therapy. His work integrates computational modeling, medicinal chemistry, and pharmacodynamics to create targeted therapies aimed at epigenetic modulation and apoptosis induction in cancer cells. He has actively contributed to national-level projects exploring dual-target inhibitors (MMP/HDAC) and small molecule interventions for Mcl-1 and striatal enriched tyrosine phosphatase (STEP) targets. Dr. Liang is particularly recognized for his innovation in optimizing chemical scaffolds for selective inhibition and minimizing off-target effects. Through collaborative and independent research, he aims to address challenges in chemotherapeutic resistance and toxicity. His scientific pursuits align with current global trends in precision oncology, making significant strides in targeted therapy development and laying a foundation for future clinical translation.

📚 Publications Top Notes:

  1. 📘 Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor – Bioorganic Chemistry, 2025

  2. 📗 Targeting histone deacetylases for cancer therapy: Trends and challenges – Acta Pharmaceutica Sinica B, 2023

  3. 📙 Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis – European Journal of Medicinal Chemistry, 2021

  4. 📕 Design, synthesis and biological evaluation of 3,4-disubstituted-imidazolidine-2,5-dione derivatives as HDAC6 selective inhibitors – European Journal of Medicinal Chemistry, 2021

  5. 📘 Recent Development of Novel HDAC6 Isoform-selective Inhibitors – Current Medicinal Chemistry, 2021

  6. 📗 HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells – Journal of Medicinal Chemistry, 2020

  7. 📙 Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors – ACS Medicinal Chemistry Letters, 2019

  8. 📕 Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives – Chinese Journal of Organic Chemistry, 2016

🧾 Conclusion:

Dr. Tao Liang is highly suitable for the Best Researcher Award, especially in the early- to mid-career researcher category. His extensive publication record, innovative medicinal chemistry work, leadership in funded projects, and impressive academic recognitions make him an exemplary candidate.

Moara Lemos | Cell Structure Analysis | Best Researcher Award

Published on by Cell Biologist

Dr. Moara Lemos | Cell Structure Analysis | Best Researcher Award

Dr. Moara Lemos, UFRJ/CENABIO, Brazil

Dr. Moara Lemos is a Brazilian parasitologist and structural biologist known for her expertise in protozoology, especially focusing on trypanosomatids. Born in Carmo do Rio Claro, Brazil, she earned her PhD in Microbiology from the Federal University of Rio de Janeiro (UFRJ). Her work bridges advanced imaging technologies, such as cryo-electron tomography, with molecular parasitology, exploring host-parasite interactions in fish and amphibians. Currently based at Institut Pasteur and UFRJ, she leads cutting-edge projects in cellular ultrastructure, nanobiotechnology, and the molecular characterization of parasites. She has received multiple research scholarships and international recognition through high-impact publications and awards. A highly collaborative scientist, Dr. Lemos has contributed significantly to parasitology, cryo-microscopy, and biomedicine, making her a strong candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Extensive Expertise in Parasitology and Cell Biology

    • Specialized in protozoology, with deep research in Trypanosoma species affecting both aquatic vertebrates and humans.

    • Combines taxonomy, ultrastructure, phylogeny, and host-parasite interactions, contributing significantly to neglected areas in parasitology.

  2. Cutting-edge Methodological Proficiency

    • Strong command over electron microscopy, including cryo-electron tomography, FIB-SEM, and correlative light and electron microscopy (CLEM).

    • Her techniques are pivotal in advancing the 3D visualization of cellular and viral structures, which is particularly impactful in infectious disease research.

  3. Translational Research Impact

    • Active participation in COVID-19-related structural virology, aiming to guide vaccine and therapeutic development.

    • Current projects focus on flagellar biogenesis, nanobiomaterials, and telepathology, integrating basic science with clinical relevance.

  4. Collaborative and International Research Network

    • Collaboration with prestigious institutions such as the Institut Pasteur, João Lobo Antunes Institute, EMBO, and CBPF.

    • Involved in multidisciplinary teams with researchers like Dorit Hanein and Philippe Bastin, increasing the credibility and reach of her research.

  5. Recognized Scientific Output

    • Publications in high-impact journals like Nature Communications, Journal of Cell Biology, *

🛠️ Areas for Improvement:

While her qualifications are substantial, a few areas could further elevate her candidacy:

  1. Greater Independent Leadership on High-Profile Projects

    • While she is a co-author on several collaborative works, leading more first-author or corresponding-author publications in top-tier journals would further establish her scientific independence.

  2. Increased Outreach or Policy Engagement

    • Expanding her influence beyond academic research—e.g., contributing to national or international policy on parasitic diseases, public health, or biodiversity conservation—could broaden impact.

  3. Clearer Documentation of Teaching/Mentorship Impact

    • While the CV lists student supervision (MSc, PhD), a dedicated summary on mentorship outcomes (e.g., students’ careers, theses supervised) would strengthen the case.

  4. Visibility in International Conferences as Speaker

    • More keynote/plenary presentations or chairing roles at major international meetings would reinforce her leadership in the field.

🎓 Education:

Dr. Lemos holds a Bachelor’s degree in Biological Sciences from the Federal University of Juiz de Fora (UFJF), where she also completed a Master’s degree in Zoology. She earned her PhD in Science (Microbiology) from the Federal University of Rio de Janeiro (UFRJ), with a dissertation on the taxonomy and host-parasite interactions of trypanosomes in Brazilian fish. Her postgraduate journey continued with multiple postdoctoral fellowships at institutions like the Institut Pasteur (France), CBPF (Brazil), and UFRJ, specializing in parasitology, biotechnology, and cryo-electron microscopy. She also pursued extensive complementary training in microscopy, cryo-ET, and molecular biology through EMBO and SBMM courses. Her education reflects a strong interdisciplinary foundation combining zoology, microbiology, biotechnology, and imaging technologies—crucial for investigating infectious diseases at a cellular and molecular level.

🎓 Education:

Dr. Lemos holds a Bachelor’s degree in Biological Sciences from the Federal University of Juiz de Fora (UFJF), where she also completed a Master’s degree in Zoology. She earned her PhD in Science (Microbiology) from the Federal University of Rio de Janeiro (UFRJ), with a dissertation on the taxonomy and host-parasite interactions of trypanosomes in Brazilian fish. Her postgraduate journey continued with multiple postdoctoral fellowships at institutions like the Institut Pasteur (France), CBPF (Brazil), and UFRJ, specializing in parasitology, biotechnology, and cryo-electron microscopy. She also pursued extensive complementary training in microscopy, cryo-ET, and molecular biology through EMBO and SBMM courses. Her education reflects a strong interdisciplinary foundation combining zoology, microbiology, biotechnology, and imaging technologies—crucial for investigating infectious diseases at a cellular and molecular level.

🏅 Awards and Honors:

Dr. Moara Lemos has received numerous accolades throughout her career. She won the Best Poster Presentation at the Institut Pasteur and the VIII International Symposium of Fish Parasites, along with the Best Oral Presentation Award at Sembio 2007. She was also recognized at the IV Annual Meeting of the National Institute of Science and Technology in Structural Biology and Bioimaging (INBEB). She has been a scholarship holder from multiple funding bodies, including CNPq, CAPES, FAPERJ, and FAPEMIG, for her postgraduate and postdoctoral research. In addition, she contributed to groundbreaking studies published in Nature Communications, Journal of Cell Biology, and American Journal of Human Genetics, earning visibility in high-impact journals. These honors highlight her impactful contributions to biomedical research, particularly in parasitology and cryo-structural biology.

🔬 Research Focus:

Dr. Lemos focuses on parasitic protozoa, especially trypanosomes, examining their ultrastructure, taxonomy, host-parasite dynamics, and intraflagellar transport mechanisms. She employs advanced imaging technologies, including cryo-electron tomography, to study the 3D cellular architecture of infectious organisms like Trypanosoma cruzi. Her research expands to the SARS-CoV-2 virus, developing cryo-microscopy workflows to analyze virus-antibody interactions. She also explores nanobiomaterials’ interactions with eukaryotic cells, combining cell biology, structural biology, and electron microscopy. Current projects include implementing telemicroscopy in Brazil’s public health system (SUS) and developing AI tools for pathology imaging. Her goal is not only to advance scientific knowledge but also to translate findings into public health and ecological conservation strategies. Dr. Lemos’ integrative and technological approach to biology makes her research highly innovative and socially relevant.

📚 Publications Top Notes:

  1. 📘 Advances, challenges, and applications of cryo‐electron tomography workflows for three‐dimensional cellular imaging of infectious pathogens – Journal of Microscopy (2025)

  2. 🧪 Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tract – bioRxiv (2022)

  3. 🔬 Morphological control enables nanometer-scale dissection of cell-cell signaling complexes – Nature Communications (2022)

  4. 🧬 Timing and original features of flagellum assembly in trypanosomes during development in the tsetse fly – Parasites & Vectors (2020)

  5. 🐸 Caracterização morfológica e morfométrica dos tripanossomas de anuros do Centro-Oeste brasileiro – Revista Brasileira de Zoociências (2019)

  6. 🧫 Biallelic Mutations in LRRC56…Cause Mucociliary Clearance and Laterality Defects – American Journal of Human Genetics (2018)

  7. 🧭 Bidirectional intraflagellar transport is restricted to two sets of microtubule doublets in the trypanosome flagellum – Journal of Cell Biology (2018)

  8. 📗 Contribuição ao estudo da biologia dos Tripanossomas de Anuros neotropicais – Thesis, UFJF (2017)

🏁 Conclusion: 

Dr. Moara Lemos demonstrates a rare combination of technical excellence, innovative research, international collaboration, and consistent productivity in fields that have both scientific importance and global health relevance. Her research in trypanosome biology, electron microscopy, and pathogen-cell interaction is critical for both basic science and applied biomedical research.

Minjian Chen | Metabolism | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Minjian Chen | Metabolism | Best Researcher Award

Prof. Dr. Minjian Chen, Nanjing Medical University, China

Professor Minjian Chen is a leading academic in toxicology and reproductive health at Nanjing Medical University (NMU). After earning both his Bachelor’s in Preventive Medicine (2008) and Ph.D. in Toxicology (2013) at NMU, he undertook postdoctoral research there and served as a guest researcher at the U.S. National Institute of Environmental Health Sciences (NIEHS), NIH. Since 2023, he has held a professorial position and was recognized as an Outstanding Young Backbone Teacher in Jiangsu’s prestigious “Qinglan Project.” His work spans reproductive toxicity, metabolomics, and exposomics, focusing on environmental and nutritional factors affecting fertility. With over 10 funded national and provincial research projects and numerous peer-reviewed publications, Professor Chen has significantly contributed to understanding spermatogenic dysfunction and metabolic profiling in reproductive biology. He continues to push boundaries in public health and environmental toxicology.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Strong Academic Foundation

    • Bachelor’s and Ph.D. in Preventive Medicine and Toxicology from a top Chinese institution (Nanjing Medical University).

    • Postdoctoral research and international exchange experience, including at the U.S. National Institute of Environmental Health Sciences (NIH/NIEHS).

  2. Outstanding Research Leadership

    • Principal Investigator (PI) for multiple competitive national and provincial grants, with over ¥2 million in individual research funding and participation in projects exceeding ¥70 million total budget.

    • Active contributor in 11 funded research projects, with core themes on reproductive toxicology, metabolomics, and AI-based diagnostics.

  3. High-Impact Publications

    • Recent publications in top-tier international journals including EMBO Journal, Molecular & Cellular Proteomics, IJMS, Theriogenology, and Toxics.

    • Regular authorship and collaborations on cutting-edge studies in exposomics, spermatogenesis, and reproductive metabolomics.

  4. Recognition and Honors

    • Named Outstanding Young Backbone Teacher under Jiangsu’s “Qinglan Project”.

    • Appointed Distinguished Young Academic Leader at Nanjing Medical University.

  5. Interdisciplinary & Translational Approach

    • Work spans basic toxicology, systems biology, and big-data-driven clinical research, positioning him well for translational impact in reproductive health and environmental medicine.

⚠️ Areas for Improvement:

  1. Expanded Global Visibility

    • While Prof. Chen has published widely, further collaboration with global institutions could help amplify international recognition.

  2. Clinical Translation

    • While he has contributed to diagnostic R&D and cohort-based studies, greater emphasis on real-world clinical application or intervention trials could boost impact and societal benefit.

  3. Leadership in Multi-National Consortia

    • Assuming leadership roles in global consortia or organizations could further solidify his position as a top-tier researcher.

🎓 Education:

Professor Minjian Chen pursued his entire academic training at Nanjing Medical University, beginning with a Bachelor’s degree in Preventive Medicine from 2003 to 2008. His passion for understanding environmental impacts on human health led him to complete a Ph.D. in Toxicology between 2008 and 2013. During his doctoral studies, he specialized in reproductive toxicology, investigating the metabolic mechanisms by which environmental toxins affect male fertility. Following his doctorate, he deepened his expertise with postdoctoral training (2013–2018) at the NMU School of Basic Medicine. In 2014, he was selected for the China–Australia Young Scientist Exchange Program, an early recognition of his academic promise and leadership. His international exposure was further enhanced through a research fellowship at the U.S. National Institute of Environmental Health Sciences (NIH) from 2019 to 2020. This robust educational background laid a strong foundation for his research in reproductive health, metabolomics, and environmental toxicology.

💼 Experience:

Professor Chen began his academic career as a Lecturer at NMU in 2013, shortly after completing his Ph.D. Over the following decade, he rose through the ranks, becoming a Professor in 2023, thanks to his prolific research and educational contributions. Between 2013 and 2018, he completed an intensive postdoctoral fellowship at NMU, focusing on toxicological studies related to male reproductive health. In 2019–2020, he broadened his global research experience by joining the NIEHS at the U.S. NIH as a guest researcher. His teaching and mentorship have earned him several accolades, including Distinguished Young Academic Leader at NMU and Outstanding Young Backbone Teacher in Jiangsu’s “Qinglan Project.” Professor Chen also plays a vital role in large-scale, national R&D programs and key provincial projects in China, acting as a Principal Investigator (PI) or Sub-project PI in more than ten funded initiatives in toxicology, reproductive biology, and data-driven diagnostics.

🔬 Research Focus:

Professor Minjian Chen’s research is centered on environmental toxicology, reproductive health, and metabolomics. His primary scientific contributions lie in uncovering how environmental toxins—including phytochemicals, metals, and industrial chemicals—disrupt male fertility through metabolic pathways. His studies on arachidonic acid metabolism, n-6 PUFA pathways, and sorbitol metabolism have advanced our understanding of oligospermia and other reproductive dysfunctions. More recently, Professor Chen has explored the application of integrative omics (metabolomics + transcriptomics) in reproductive cells like oocytes and cumulus cells, providing insights into fertility and early development. He is also involved in big-data-driven diagnosis for pregnancy complications such as intrahepatic cholestasis and macrosomia, and in nationwide projects investigating genetic risks in ART offspring and structural birth defects. His work is highly interdisciplinary, blending toxicology, biochemistry, epidemiology, and computational biology to push the frontiers of precision reproductive health and environmental health sciences.

📚 Publications Top Notes:

  1. 🧬 Association of Personal Care and Consumer Product Chemicals with Long-Term Amenorrhea: Insights into Serum Globulin and STAT3 (Toxics, 2025)

  2. 🧫 Characterization of Metabolic Patterns in Mouse Spermatogenesis and Its Clinical Implications in Humans (IJMS, 2025)

  3. 🧪 A Metabolome and Microbiome Analysis of Acute Myeloid Leukemia: Insights into the Carnosine–Histidine Metabolic Pathway (Toxics, 2024)

  4. 🐷 Characterization of Metabolic Patterns in Porcine Cumulus Cells During Meiotic Maturation (Theriogenology, 2024)

  5. 🐐 Combined Analysis of Temporal Metabolomics and Transcriptomics in Goat Oocytes During Maturation (Theriogenology, 2024)

  6. 🧍 Exposure to Molybdate Results in Metabolic Disorder: Urine Elementome and Serum Metabolome in Mice (Toxics, 2024)

  7. 🧬 Integrative Omics Reveals the Metabolic Patterns During Oocyte Growth (Molecular & Cellular Proteomics, 2024)

  8. 🌐 The Global Phosphorylation Landscape of Mouse Oocytes During Meiotic Maturation (EMBO Journal, 2024)

  9. ⚗️ Environmental Chemical Exposomics and Metabolomics in Toxicology: The Latest Updates (Toxics, 2024)

  10. 👶 Cohort Profile: The Jiangsu Birth Cohort (International Journal of Epidemiology, 2023)

📝 Conclusion:

Professor Minjian Chen is highly suitable for the Best Researcher Award. His consistent research excellence, broad project leadership, publication strength, and interdisciplinary work make him a standout candidate. His research is not only scientifically rigorous but also socially relevant—targeting reproductive health challenges through environmental and metabolic lenses. With additional emphasis on global outreach and clinical application, Prof. Chen’s impact could become even more transformative.

Xiaozhi Liu | Cell-Cell Communication | Best Researcher Award

Published on by Cell Biologist

Prof. Xiaozhi Liu | Cell-Cell Communication | Best Researcher Award

Prof. Xiaozhi Liu, Tianjin Fifth Central Hospital, China

Dr. Xiaozhi Liu, born on December 10, 1979, is a distinguished medical researcher and Director of the Central Laboratory at Tianjin Fifth Central Hospital. With over two decades of experience in neurosurgery and translational research, he has made substantial contributions in neural regeneration and SUMOylation-related mechanisms. Dr. Liu is a prolific academic with numerous publications in top-tier journals and active involvement in multiple National Natural Science Foundation of China projects. His international exposure as a visiting scholar at Duke University Medical Center (2012–2013) enhanced his global scientific perspective. Dedicated to neuroscience innovation, he combines advanced molecular biology techniques with clinical applications to improve patient outcomes in neurological disorders. Recognized for his scientific rigor, leadership, and innovative research approach, Dr. Liu is an exceptional candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Innovative Research Focus: Dr. Liu’s expertise in SUMOylation, neural regeneration, and gene regulation presents a cutting-edge approach to treating cerebral ischemia, glioblastoma, and cardiac injury.

  2. Strong Grant History: He has led multiple prestigious National Natural Science Foundation of China (NSFC) projects as both PI and co-investigator, with substantial funding and scientific merit.

  3. Impressive Publication Record: Over 15 peer-reviewed publications in impactful journals (Stroke, Aging, Neuroscience, etc.), with topics ranging from brain ischemia to cardiac injury, illustrate interdisciplinary strength.

  4. Leadership Role: As Director of the Central Laboratory, he demonstrates strong research management, mentoring, and institutional collaboration capabilities.

  5. Global Perspective: His time as a visiting scholar at Duke University Medical Center enhanced his academic and cross-cultural research competencies.

  6. Clinical & Basic Science Integration: Combines bench-to-bedside applications, especially in neurosurgery and molecular biology.

⚠️ Areas for Improvement:

  1. International Outreach: While academically robust in China, Dr. Liu could benefit from increased global collaboration, co-authorship with foreign institutes, or keynote speaking roles at international conferences.

  2. Patent & Innovation Translation: There’s potential to strengthen the translational commercialization of his research findings through patents or biotech partnerships.

  3. Public Engagement: Increasing public science communication and media presence could enhance his visibility in broader scientific and policy-making communities.

🎓 Education Background:

Dr. Xiaozhi Liu began his academic journey at Zhangjiakou Medical College, completing a degree in Clinical Medicine in 2003. He pursued his passion for neurosurgery at Tianjin Medical University, where he earned a master’s degree in 2007 and later a Ph.D. in 2017. His academic pursuit extended internationally with a one-year research fellowship at the Duke University Medical Center in the United States (2012–2013), where he specialized in neurosurgical studies. Throughout his academic training, Dr. Liu has demonstrated a deep commitment to the integration of clinical knowledge with cutting-edge biomedical research, particularly in the areas of neuroregeneration and molecular neuroscience. His academic background laid a strong foundation for his contributions to neurobiology, clinical translation, and innovative research in SUMOylation, gene expression regulation, and therapeutic interventions for neurological diseases.

🏥 Work Experience:

Dr. Liu began his clinical career as a Neurosurgery Resident at the Affiliated Hospital of the Chinese People’s Armed Police Force Medical College from 2007 to 2009. He then served as a physician in the Department of Neurosurgery at Tianjin Fifth Central Hospital until 2012. Since December 2013, he has been serving as the Director of the Central Laboratory at the same institution. In this role, he has spearheaded major research initiatives and supervised clinical translational projects in neurobiology. His leadership has been instrumental in establishing a multidisciplinary research environment that bridges clinical neuroscience and molecular biology. His extensive experience in both hospital-based patient care and laboratory-based scientific discovery places him at the intersection of clinical excellence and research innovation. His career trajectory reflects an unwavering commitment to advancing medical science and improving patient care.

🔬 Research Focus:

Dr. Xiaozhi Liu’s research centers on the molecular mechanisms of neuroregeneration, focusing particularly on SUMOylation, gene expression modulation, and neural stem cell therapy. His work explores the protective roles of SUMO-modified proteins in ischemic stroke, glioblastoma suppression, and spinal cord injury recovery. Dr. Liu investigates the role of small RNAs, mitochondrial dynamics, and oxidative stress in neurodegenerative conditions and cardiovascular diseases. His approach combines genomic, proteomic, and cell-based assays to understand the therapeutic potential of modulating cellular stress responses. Ongoing collaborations on stem cell transplantation, chromatin remodeling in cardiac diseases, and translational neuroscience further exemplify his dedication to interdisciplinary science. With an extensive list of national research grants and peer-reviewed publications, Dr. Liu remains at the forefront of biomedical innovations aimed at reversing tissue damage and enhancing neuroplasticity.

📚 Publication Top Notes:

  1. 🧠 Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in transgenic mice – Stroke, 2014

  2. 🧬 Interactions of connexin 43 and aquaporin-4 in glioma-induced brain edema – Mol Med Rep, 2015

  3. 🧠 Neuron-specific SUMO knockdown worsens outcome after brain ischemia in mice – Neuroscience, 2017

  4. 🦴 Silencing Ubc9 suppresses osteosarcoma and enhances chemosensitivity via Connexin 43 SUMOylation – Int J Oncol, 2018

  5. ❤️ SERCA2a: a key protein in the calcium cycle of heart failure – Heart Fail Rev, 2019

  6. 💓 Zinc-induced SUMOylation of Drp1 protects heart from ischemia-reperfusion injury – Oxid Med Cell Longev, 2019

  7. 🧠 Genetic polymorphisms and transcription in intracranial aneurysm involving NOTCH3 – Aging (Albany NY), 2019

  8. 🧪 Saikosaponin-d inhibits hepatoma and enhances chemosensitivity via SENP5-dependent Gli1 SUMOylation – Front Pharmacol, 2019

  9. 🧬 Parkin and Nrf2 prevent apoptosis in endplate chondrocytes via mitophagy – Life Sci, 2019

  10. 🧫 MitoQ protects against disc degeneration by targeting mitochondrial dysfunction – Cell Prolif, 2020

🧾 Conclusion:

Dr. Xiaozhi Liu stands out as a highly qualified and deserving candidate for the Best Researcher Award. His blend of clinical neurosurgery, translational laboratory research, and molecular innovation, particularly in SUMOylation and neuroprotection, positions him at the forefront of modern biomedical science in China. With a leadership role in a major hospital, strong national research recognition, and a substantial academic footprint, he exemplifies excellence in research and mentorship.

Basavaraj Vastrad | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Dr. Basavaraj Vastrad | Gene Regulation Epigenetics | Best Researcher Award

Dr. Basavaraj Vastrad, KLE College of Pharamac, Gadag, karanataka 582101, India

Dr. Basavaraj Vastrad is a distinguished Indian scientist specializing in pharmaceutical biotechnology and bioinformatics. With over 15 years of research experience, his work bridges cutting-edge genomics, next-generation sequencing (NGS), and computational biology to uncover genetic underpinnings of complex diseases like Alzheimer’s, diabetes, schizophrenia, and various cancers. He holds a Ph.D. in Biochemistry from Kuvempu University and a Master’s in Pharmaceutical Biotechnology from JSS College of Pharmacy. A prolific researcher, Dr. Vastrad has contributed to over 25 impactful publications in reputed international journals. His collaborative efforts with interdisciplinary teams have yielded novel insights and molecular targets for diseases with high clinical burden. Recognized for his methodical approach and academic excellence, Dr. Vastrad has emerged as a thought leader in bioinformatics-driven drug discovery and disease modeling. With a deep commitment to translational research, he continues to shape the scientific understanding of human health and disease.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Dr. Vastrad has published over 25 high-quality research articles, many in international, peer-reviewed, indexed journals. His work spans crucial fields including bioinformatics, genomics, neurodegenerative diseases, cardiovascular disorders, and reproductive health.

  2. Focus on Translational Research
    His research directly addresses major global health concerns—Alzheimer’s, Huntington’s, diabetes, PCOS, schizophrenia, and cardiovascular diseases—using next-generation sequencing (NGS) and computational biology. This demonstrates not only scientific depth but also clinical relevance.

  3. Strong Bioinformatics Expertise
    Dr. Vastrad applies state-of-the-art bioinformatics tools and techniques to identify novel biomarkers, therapeutic targets, and disease-related pathways, offering substantial contributions to personalized medicine and drug discovery.

  4. Solid Foundation in Biochemistry and Biotechnology
    With a Ph.D. in Biochemistry and a Master’s in Pharmaceutical Biotechnology, he brings a robust interdisciplinary background that supports a holistic approach to research problems.

  5. Experience in Microbial Biotechnology and SSF
    His earlier work on solid-state fermentation (SSF) for antibiotic production from agro-industrial waste reflects his ability to integrate sustainability with industrial biotechnology.

  6. Collaborative and Multidisciplinary Approach
    His collaborations with researchers across domains (pharmacology, genetics, medicine, and bioinformatics) showcase a team-oriented and integrative research mindset.

⚠️ Areas for Improvement:

  1. International Recognition and Grants
    While his publication record is excellent, securing global research grants, international collaborations, and patents would further enhance his global research standing.

  2. Innovation Translation
    Translating his bioinformatics discoveries into patents, prototypes, or clinical tools would significantly amplify the societal impact of his work.

  3. Leadership in Research Communities
    Serving on editorial boards, leading consortia, or contributing to scientific policy and outreach would help extend his influence in the scientific community.

🎓 Education:

Dr. Basavaraj Vastrad’s academic journey began with a Bachelor’s in Pharmacy from K.L.E’s College of Pharmacy, Hubli under RGUHS, Bangalore, completed in 2003. He pursued his Master of Pharmacy in Pharmaceutical Biotechnology from J.S.S. College of Pharmacy, Ootacamund (affiliated to The Tamil Nadu Dr. M.G.R. Medical University), which he completed in 2006. Driven by his passion for biomedical research, he earned his Ph.D. in Biochemistry from Kuvempu University, Shimoga, in 2013. His academic training is rooted in pharmaceutical sciences, molecular biology, and biotechnological applications, providing him a strong foundation in both experimental and computational research methodologies. Dr. Vastrad’s educational background reflects a harmonious blend of practical pharmaceutical knowledge and bioinformatics expertise—skills he now applies to genomics, drug discovery, and disease pathway elucidation. Each academic milestone laid the groundwork for his prolific research career focused on solving health-related challenges through innovative approaches.

👨‍🔬 Experience:

Dr. Basavaraj Vastrad has an extensive research and teaching experience spanning over a decade, primarily focusing on pharmaceutical biotechnology, solid-state fermentation, and bioinformatics. Early in his career, he specialized in microbial techniques, including antimicrobial assays and sterility testing. He later advanced to complex genomic data analysis using NGS and bioinformatics tools to decode molecular mechanisms behind various human diseases. His contributions have been instrumental in identifying biomarkers and therapeutic targets for disorders such as Alzheimer’s, schizophrenia, cardiovascular diseases, and metabolic syndromes. Collaborating with clinical and academic institutions, he has co-authored several high-impact research papers. He has also mentored junior researchers and contributed to numerous interdisciplinary studies. Dr. Vastrad’s experience in solid-state fermentation has led to optimized antibiotic production using agro-industrial waste, showcasing his ability to translate basic science into practical applications. His work stands out for its scientific rigor, innovative approaches, and potential for real-world clinical impact.

🔬 Research Focus:

Dr. Basavaraj Vastrad’s research is primarily centered around the application of bioinformatics and next-generation sequencing (NGS) to investigate the genetic and molecular basis of complex diseases. His projects have successfully decoded the signaling pathways, biomarkers, and therapeutic targets associated with conditions like Alzheimer’s disease, Huntington’s disease, PCOS, heart failure, endometriosis, schizophrenia, and various cancers. Another aspect of his research explores solid-state fermentation for the optimization of antibiotic production, using agro-industrial waste as a substrate. Dr. Vastrad applies computational tools to perform gene expression profiling, pathway enrichment, molecular docking, and biomarker identification. He also collaborates extensively with clinicians and scientists in integrating bioinformatics findings into potential translational therapies. His focus on data-driven diagnostics and personalized medicine represents a blend of computational science with tangible health outcomes. His goal is to harness bioinformatics for predictive diagnostics, therapeutic development, and a deeper understanding of pathophysiological mechanisms.

📚 Publications Top Notes:

  1. 🔍 Bioinformatics analysis of NGS data to diagnose crucial and novel genes in gestational diabetes mellitus

  2. 🧠 Identification of key genes in Huntington’s disease using NGS and bioinformatics

  3. 🧬 Analysis of Alzheimer’s disease pathways using NGS and computational approaches

  4. 🧘‍♂️ Key gene identification in schizophrenia using NGS-based bioinformatics

  5. 👩‍⚕️ Polycystic ovary syndrome: bioinformatics-based gene pathway identification

  6. ❤️ Myocardial infarction: NGS-driven bioinformatics marker analysis

  7. 👩 Endometriosis biomarkers identified using bioinformatics and NGS

  8. 🌬 Gene expression in idiopathic pulmonary fibrosis via bioinformatics and NGS

  9. 🔬 Molecular markers in pancreatic ductal adenocarcinoma using bioinformatics

  10. 💓 Heart failure: discovery of genes and pathways through NGS data

🧾 Conclusion:

Dr. Basavaraj Vastrad is highly deserving of the Best Researcher Award. His consistent contributions to bioinformatics and pharmaceutical biotechnology, innovative approaches to disease genomics, and impactful publications demonstrate scientific excellence, depth, and relevance. He not only pushes the boundaries of current biomedical knowledge but also aligns his work with pressing healthcare needs.

Flavia Neto de Jesus | Molecular Mechanisms Signaling | Best Research Article Award

Published on by Cell Biologist

Dr. Flavia Neto de Jesus | Molecular Mechanisms Signaling | Best Research Article Award

Dr. Flavia Neto de Jesus, Texas A&M University, United States

Dr. Flavia Neto de Jesus is a passionate research scientist with a PhD in Pharmacology from the University of São Paulo and over a decade of experience in preclinical and translational research. She specializes in inflammation, reactive oxygen species (ROS), vascular physiology, and lymphatic system disorders, particularly in the context of arthritis and cancer. Currently a Postdoctoral Researcher in Canada, Dr. de Jesus has developed extensive skills in molecular biology, vascular imaging, and functional assays. Her multidisciplinary research contributes to advancing knowledge in immunopathology, lymphatic remodeling, and endothelial function. Widely published and recognized in her field, she has received awards for her scientific contributions and actively mentors students and collaborates across diverse research teams. Her work bridges pharmacological mechanisms with clinically relevant models, demonstrating both scientific rigor and innovation.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Originality & Scientific Merit:
    Dr. de Jesus’s work on lymphatic physiology, inflammation, and reactive oxygen species stands out for its mechanistic depth and translational relevance. Her findings related to NOX inhibition, acetylcholine-mediated vasodilation, and lymphatic hyperactivity in arthritis present novel therapeutic insights.

  2. High-Impact Publications:
    Published in respected journals such as PNAS, Life Sciences, Antioxidants, Biomolecules, and Microcirculation, her research demonstrates a consistent track record of scientific excellence.

  3. Award-Winning Contribution:
    The 2023 Travel Award from the Lymphatic Forum for a detailed vascular-laboratory-based study highlights peer recognition and confirms the value of her contributions to lymphatic research.

  4. Advanced Methodology:
    She applies cutting-edge techniques in animal models, functional vascular assessments, and molecular biology—key components that strengthen the scientific rigor of her articles.

  5. Interdisciplinary Relevance:
    Her research links vascular biology, immunology, and pharmacology, adding significant value across disciplines including rheumatology, oncology, and metabolic disease.

⚠️ Areas for Improvement:

  1. Pending Publications:
    A few of her strongest recent manuscripts are still under review or in preparation. Their final publication would bolster her visibility and add further weight to her candidacy.

  2. Broader International Outreach:
    While her collaborations are robust, engaging more with international institutions beyond North and South America could further amplify the global impact of her work.

  3. Clear Highlight of Novelty in Abstracts:
    While the research is rich in content, abstracts and titles could more clearly emphasize novelty and real-world implications to stand out for award nominations.

🎓 Education:

Dr. Flavia Neto de Jesus earned her PhD in Pharmacology from the University of São Paulo, one of Brazil’s premier institutions for biomedical research. During her graduate studies (2011–2019), she focused on vascular biology and inflammation, developing deep expertise in endothelial dysfunction, nitric oxide signaling, and lymphatic-arterial cross-regulation. Her early academic journey included foundational studies in biology and pharmacological techniques, enriched by rigorous laboratory practice and collaborative research. To complement her ethical and methodological framework, she completed the TCPS2 training (Ethical Conduct for Research Involving Humans) in 2024 in Calgary, Canada. This has enabled her to work seamlessly in both Brazilian and Canadian research environments. Her education reflects a strong grounding in both experimental and translational science, empowering her to contribute meaningfully to complex biomedical challenges.

🧪 Professional Experience:

Since April 2019, Dr. Flavia Neto de Jesus has been working as a Postdoctoral Researcher focusing on inflammation-related mechanisms in arthritis, fibrosis, and cancer-associated lymphatic changes. Her role encompasses designing and executing in vivo studies, molecular biology experiments, and vascular function assessments. She leads laboratory operations, supervises student researchers, and contributes significantly to manuscript development and conference presentations. Her contributions to the field include pioneering insights into lymphatic dysfunction, ROS involvement in vascular remodeling, and endothelial channel regulation. With over a decade in pharmacological research, Dr. de Jesus has cultivated a rich portfolio of publications and collaborations across interdisciplinary teams. Her experience reflects a strong command over both experimental methodology and collaborative science, making her a valuable contributor in both academic and applied research settings.

🏅 Awards and Honors:

Dr. Flavia Neto de Jesus has been recognized for her significant contributions to lymphatic system research. Notably, she received the Travel Award in 2023 from the Lymphatic Forum Conference for her impactful abstract: “Decreased contraction frequency by NOX inhibition and ACh-mediated vasodilation in hyperactive popliteal afferent lymphatic vessels in a TNFα-induced spontaneous arthritis mouse model.” This award acknowledged her advanced understanding of vascular and immune interplay in chronic inflammation. Additionally, she has participated in prestigious international conferences, such as the 19th World Congress of Basic & Clinical Pharmacology, where her work on NOS and NOX regulation in lymphatics was presented. These honors reflect her growing recognition within the vascular biology and pharmacology communities, underscoring her potential as a leader in translational immunovascular research.

🔬 Research Focus:

Dr. de Jesus’s research focuses on the interplay between inflammation, oxidative stress, and vascular dysfunction—especially within the context of the lymphatic system. Her work investigates how reactive oxygen species (ROS), nitric oxide signaling, and molecular pathways like NADH oxidase (NOX) and endothelin (ET) regulate lymphatic vessel contractility and remodeling. Her current postdoctoral work explores lymph node immunobiology, arthritis models, and cancer-lymphatic interactions using sophisticated in vivo and molecular approaches. She integrates vascular physiology with immunology, seeking to unravel how inflammation alters lymphatic transport, immune cell trafficking, and endothelial responses. Her studies often leverage genetically modified mouse models and combine functional assays with histological, biochemical, and transcriptomic analyses. Dr. de Jesus’s research offers novel insights into pathophysiological processes underlying chronic diseases such as arthritis, fibrosis, and cancer, positioning her at the forefront of lymphovascular research.

📚 Publications Top Notes:

📖 Hyperactive popliteal lymphatic vessels require activation of NADH oxidase (NOX) and endothelin (ET) pathways in arthritic mice (In prep)
📖 Microbiota is dispensable for lymphatic vessel hyperactivity in the TNFΔARE/+ mouse model – Arthritis Rheumatology (Under revision)
📖 Dysregulated lymphatic remodeling promotes immunopathology during non-healing cutaneous leishmaniasis – Cell Press (Under review)
📖 Presence of dysfunctional soluble guanylate cyclase in mesenteric arteries from periodontitis rats – European J. of Pharmacology (2025)
📖 Flow-dependent regulation of mesenteric lymphatic vessels via TRPV4 activation – Microcirculation (2023)
📖 Increased contractile activity and dilation of lymphatic vessels in TNF-α-overexpressing arthritic mice – Life Sciences (2023)
📖 Lymph-derived chemokines drive neutrophil infiltration in lymph nodes post-S. aureus infection – PNAS (2022)
📖 Nutraceutical mix modulates gene expression in Type-2 Diabetes Obesity Model – Antioxidants (2022)
📖 AP39-induced vasorelaxation in mouse mesenteric arteries – Biomolecules (2022)
📖 Leukotriene receptor antagonist reduces bone loss in periodontitis – Journal of Periodontology (2021)
📖 Endothelial dysfunction in periodontitis involves NO and COX-2 products – Archives of Oral Biology (2016)
📖 Beta-alanine and sodium bicarbonate improve swimming performance – Applied Physiology, Nutrition, and Metabolism (2013)

📝 Conclusion:

Dr. Flavia Neto de Jesus is highly suitable for the Best Research Article Award. Her article on NOX inhibition and ACh-mediated vasodilation in hyperactive lymphatic vessels offers a novel mechanistic insight into the vascular pathology of inflammatory arthritis, an area with significant unmet clinical need. Her work is original, methodologically rigorous, and impactful within the field of lymphatic and vascular biology. Given her award-winning presentation, peer-reviewed track record, and interdisciplinary research value, she is a strong candidate deserving of recognition.